報價延遲最少15分鐘:2026/04/19 04:27 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7821 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.59/-0.48
|
|
企業價值
169.93M
|
| 資產負債 |
|
每股賬面淨值
0.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease. |
